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Introduction: The aims of this study were to explore the incidence of in-hospital inappropriate empiric antibiotic
use in patients with severe infection and to identify its relationship with patient outcomes.
Methods: Medline (from 2004 to 2014) was systematically searched by using predefined inclusion criteria.
Reference lists of retrieved articles were screened for additional relevant studies. The systematic review included
original articles reporting a quantitative measure of the association between the use of (in)appropriate empiric
antibiotics in patients with severe in-hospital infections and their outcomes. A meta-analysis, using a random-effects
model, was conducted to quantify the effect on mortality by using risk ratios.
Results: In total, 27 individual articles fulfilled the inclusion criteria. The percentage of inappropriate empiric
antibiotic use ranged from 14.1% to 78.9% (Q1-Q3: 28.1% to 57.8%); 13 of 27 studies (48.1%) described an incidence of
50% or more. A meta-analysis for 30-day mortality and in-hospital mortality showed risk ratios of 0.71 (95% confidence
interval 0.62 to 0.82) and 0.67 (95% confidence interval 0.56 to 0.80), respectively. Studies with outcome parameter
28-day and 60-day mortality reported significantly (P ≤0.02) higher mortality rates in patients receiving inappropriate
antibiotics. Two studies assessed the total costs, which were significantly higher in both studies (P ≤0.01).
Conclusions: This systematic review with meta-analysis provides evidence that inappropriate use of empiric antibiotics
increases 30-day and in-hospital mortality in patients with a severe infection.Introduction
Infections are among the top three leading causes of death
worldwide [1]. Septicaemia and pneumonia combined are
the sixth most common causes of death in the United
States [2]. Bloodstream infections (BSIs) are associated
with substantial morbidity, mortality, and health-care
costs [3]. Sepsis is one of the leading causes of death in
the critically ill, with a mortality rate of 28% to 55% [4].
Antibiotics are the mainstay of treatment for these serious
infections [5]. Antibiotic treatment for moderate to severe
infections has to start early and, in the absence of evidence
on the causative pathogen or its sensitivity to antibiotics,
is often guided by empirical evidence [6].* Correspondence: kristel.marquet@uhasselt.be
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unless otherwise stated.Estimates of the potential benefit of appropriate em-
pirical antibiotic treatment (AAT) vary widely [7-11].
Studies on the effect of inappropriate empiric antibiotic
therapy (IAAT) on patient outcomes have yielded variable
results [6,12]. Nevertheless, it is common wisdom that
IAAT may lead to progressive deterioration and the
development of complications or mortality [13-18].
Given the high incidence of infections and the not
well-established relationship between empiric (I)AAT
and clinical outcome [19-22], it is necessary to synthese
the best available evidence. This systematic review with
meta-analysis was conducted to synthesize the best available
evidence regarding (1) the definition, (2) the incidence,
and (3) the outcome of empiric IAAT.
Methods
Data sources and search strategy
Quantitative studies on the association between the use
of empiric (I)AAT in patients with a severe infection andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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were searched in Medline. Studies published in the last
10 years (20 August 2004 to 20 August 2014) were selected
as critical illness management changes continuously and
earlier and earlier studies may be less relevant for current
practice. The following Medical Subject Headings
(MeSH) search terms and free-text terms were used
either individually or in combination: ‘antibiotic’, ‘infec-
tion’, ‘appropriate’, ‘inappropriate’, ‘adequate’, ‘inad-
equate’, ‘outcome’, ‘mortality’, ‘survival rate’, ‘cost’, and
‘length of stay’. Only studies published in English,
Dutch, German, or French were included. Reference
lists of retrieved articles were hand-searched for add-
itional relevant studies. A detailed description of the search
strategy is included in the Additional file 1: digital content.
Eligibility criteria
Study design
Potentially included study designs included randomized
controlled trials (RCTs), non-randomized controlled trials,
controlled before-after studies, interrupted time series, and
repeated measures studies. Only studies reporting a quanti-
tative evaluation regarding the association between the use
of AAT or IAAT in patients with a severe infection and
their outcomes within the hospital setting were included.
The studies use (I)AAT as the independent variable and
outcome—measured as mortality, hospital length of stay
(LOS), and costs—as the dependent variable. Studies that
recruited less than 75 patients were excluded because the
research team assumes that these studies bear the risk to be
underpowered.
Patients
The included patients were adults (at least 18 years old)
with a severe infection. For this review, pneumonia, BSI or
bacteraemia, sepsis, severe sepsis, or septic shock were
considered severe infections. Studies specifically focused on
meningitis, endocarditis or infections in burn and trans-
plant patients were excluded as the literature showed that
treatment effects are expected to largely deviate from any
common effect.
Intervention
The intervention of interest concerned empiric AAT ver-
sus IAAT. Empiric antibiotic therapy is defined as all non-
definitive therapy and refers to antibiotics given prior to
the result of the final culture and the antibiotic sensitivity
tests [23]. Studies that did not specify the used definition
of AAT or IAAT were excluded. Studies comparing two or
more types of antibiotics were excluded.
Outcome
Outcomes were assessed in terms of mortality, hospital
LOS, and costs.Study appraisal
Two reviewers (KM and AL) independently performed
the initial scan of titles and abstracts of all retrieved
citations by using standardized screening forms. Both
reviewers documented the reasons for exclusion. Full-text
copies of all potentially relevant studies were obtained and
further checked for inclusion. Any discrepancies between
reviewers were resolved by discussion. Continuing dis-
agreements were settled by a third reviewer (NC or AV).
Additional sources that had been cross-referenced from
the Medline search results were included if they met the
criteria above. The quality of the articles was evaluated by
using the Downs and Black quality assessment method,
which is a list of 27 criteria to evaluate both randomized
and non-randomized trials [24]. This scale assesses study
reporting, external validity, internal validity, and power of
non-randomized studies and has been ranked in the top
six quality assessment scales suitable for use in systematic
reviews [25,26]. As had been done in other reviews using
the Downs and Black scale [27-29], the tool was modified
slightly for use in this particular review. Specifically, the
scoring for question 27 dealing with statistical power was
simplified to a choice of awarding either 1 point or 0
points, depending on whether there was sufficient power
to detect a clinically important effect. The criterion was
that to detect a 10% difference, assuming power of 0.90
and alpha of 0.05. The Downs and Black scores were
grouped into the following 4 quality levels: excellent (26 to
28), good (20 to 25), fair (15 to 19) and poor (less than 14)
[29]. Only articles with a quality level of good or excellent
were retained.
Data extraction
Data extraction was completed independently by two
reviewers (KM and AL), who used a standardized data
collection form. The following data were extracted and
reported: (1) data on study setting and patient population
as possible confounding factors, (2) definition and inci-
dence of the (I)AAT, and (3) definition and measurement
of outcome variables (in terms of mortality, hospital LOS,
and costs among patients given AAT versus IAAT). In
case of disagreement between the two reviewers, a third
reviewer (NC or AV) extracted the data.
Study characteristics
For every included study, descriptive data on the study
setting (that is, study design, geographic location of the
study, baseline characteristics, study years, and sample size)
and patient characteristics (that is, source of infection and
severity scale) were collected.
Definition and measuring incidence of (I)AAT
We reviewed how empiric (I)AAT was defined and
measured. We assessed which evidence-based elements,
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Empiric antibiotic therapy is defined as all non-definitive
therapy and refers to antibiotics given prior to the result
of the final culture and the antibiotic sensitivity tests [23].
Measurement of the dependent variable
The outcome was measured as mortality, LOS, and costs
for patients given empirical (I)AAT. The time span of
mortality assessment was also registered.
Data analysis
Data were analyzed by using R (a language and environment
for statistical computing) [30]. All reported P values were
two-sided; P <0.05 was considered to indicate statistical
significance. A random-effects meta-analysis using the
DerSimonian-Laird estimator obtained risk ratios (RRs)
and 95% confidence intervals (CIs) for mortality rate reduc-
tions [31]. Heterogeneity of the study results was assessed
by using the Cochran Q test and the Higgins I2 test. The
following thresholds were used to quantify heterogeneity:
P <0.10 in Cochran’s Q test and I2 ≤ 25% for low,Figure 1 PRISMA (Preferred Reporting Items of Systematic reviews an25% < I2 < 50% for moderate, and I2 ≥ 50% for high.
Funnel plots assessed publication bias. Sensitivity analysis
identified heterogeneous studies that influenced the meta-
analysis. Meta-regression was used to examine the impact of
study characteristics on study effect size and heterogeneity.
Results
Results of the search
The initial database search identified 1,097 unique citations.
Review of the reference lists of included studies identified
11 additional studies. After critical assessment of these
1,108 publications, 32 individual trials [8,12,19,21,22,32-58]
fulfilled the inclusion criteria and were considered for
further analysis (Figure 1). After quality assessment of
the individual studies, 27 studies [8,12,19,21,22,33,34,
36-48,50-52,54-57] were included in the systematic review.
Study characteristics
Characteristics of the 27 included studies are pre-
sented in Table 1. The studies were conducted in Asia
(n = 9) [8,12,21,41,44,50-52,55], North America (n = 8)d Meta-Analyses) diagram for study selection. LOS, length of stay.
Table 1 Characteristics of 27 included studies in the systematic review
Reference Study year(s) Location Design Center Number of
patients
Outcome Main type of infection Severity index scale and
significance differenceNumber Type
Kim et al. [21]a 1998-2001 Korea R 1 U 127 M MRSA bacteremia McCabe’s classification, Jackson: NS
Kang et al. [12]a 1998-2002 Korea R 2 U, G 286 M Antibiotic-resistant
Gram-negative Bacilli BSI
APACHE II: NS
Micek et al. [33]a 1997-2002 USA R 1 U 305 M Pseudomonas aeruginosa BSI SAPS II: NC
Luna et al. [34] 1999-2003 Argentina P 6 NM 76 M Pneumonia (VAP) APACHE II: NS
Kim et al. [8] 1998-2001 South Korea R 1 U 238 M SAB McCabe’s classification,
Jackson: NS
Scarsi et al. [22]a 2001-2003 USA R 1 U 884 M Gram-negative BSI Charlson index: NS
Marschall et al. [36]a 2006-2007 USA P 1 T 250 M LOS Gram-negative bacteremia Charlson index, McCabe’s
classification: NS
Shorr et al. [37]a 2002-2004 USA R 1 U 291 M LOS C MRSA infection NM
Rodríguez-Baño et al. [38]a 2003 Spain P 59 U, G 209 M Sepsis Charlson index: NC
Ammerlaan et al. [39]a 2007 West European countries R 60 T, G 334 M SAB Modified Charlson index: NS
Erbay et al. [19]a 2005-2008 Turkey R 1 U 103 M Acinetobacter baumannii bacteremia APACHE II: NC
Kumar et al. [40]a 1996-2005 Canada, USA, Saudi Arabia R 22 U 5,715 M Septic shock APACHE II: NC
Tseng et al. [41]a 2005-2007 Taiwan R 1 T 163 M Pneumonia Charlson index: NC
Micek et al. [42]a 2002-2007 USA R 1 U 760 M Gram-negative sepsis APACHE II, Charlson index: NS
Paul et al. [43]a 1999-2007 Israel R 1 NM 510 M MRSA bacteremia NM
Joung et al. [44]a 2000-2006 Korea R 1 U 116 M Pneumonia (HAP)
Acinetobacter baumannii
APACHE II: NS
Shorr et al. [45] 2002-2007 USA R 1 U 760 LOS Gram-negative sepsis APACHE II, Charlson index: NS
Suppli et al. [46]a 2002-2005 Denmark R 1 T 196 M Enterococcal BSI Charlson index: NS, except
score 0 (P = 0.04)
Reisfeld et al. [47]a 2005-2007 Israel R 1 G 378 M Gram-negative bacteremia NM
Wilke et al. [48]a 2007 Germany R 5 T 221 M LOS C Pneumonia (VAP, HAP) NM
Lye et al. [50]a 2007-2009 Singapore R 2 G 675 M Gram-negative bacteremia APACHE II <0.001; Charlson index: NS
Tseng et al. [51] 2007-2008 Taiwan R 1 U 163 M Pneumonia (VAP) APACHE II, Charlson index, SOFA: NC
Chen et al. [52] 2006-2011 China R 1 T 118 M SAB APACHE II: NC
Labelle et al. [54]a 2002-2007 USA R 1 T 436 M Septic shock APACHE II, Charlson index: NC
Chen et al. [55] 2008-2009 Taiwan P 1 U 937 M, LOS BSI MEDS, Charlson index: NC
Frakking et al. [56]a 2008-2010 The Netherlands R 8 U 232 M ESBL bacteremia Pitt bacteremia score: NS
Tumbarello et al. [57]a 2008-2010 Italy R 1 U 110 M Pseudomonas aeruginosa pneumonia SAPS II, SOFA: NS
aTwenty-one included studies in meta-analysis. APACHE II, Acute Physiology and Chronic Health Evaluation II; BSI, bloodstream infection; C, costs; ESBL, extended-spectrum β-lactamase; G, general hospital; HAP, hospital-acquired pneumonia;
LOS: Length Of Stay; M, mortality; MEDS, Mortality in Emergency Department Sepsis; MRSA, Methicillin-resistant Staphylococcus Aureus; NC, no comparison; NM, not mentioned; NS, not significant; P, prospective; R, retrospective; SAB,










Marquet et al. Critical Care  (2015) 19:63 Page 5 of 12[22,33,34,36,37,42,45,54], Europe (n = 6) [19,38,46,48,56,57],
and the Middle East (n = 2) [43,47], and two studies
were multinational [39,40]. Eight studies (29.6%) were
multicenter trials (range 2 to 60) [12,34,38-40,48,50,56].
Twenty studies (74.1%) were conducted in university or
teaching hospitals [8,19,21,22,33,36,37,40-42,44-46,48,51,
52,54-57], three studies (11.1%) combined university and
general hospitals [12,38,39], two studies (7.4%) were
performed in general hospitals [47,50], and two studies
(7.4%) did not mention the nature of the site [34,43].
Twenty-three studies (85.2%) reported on retrospective
analysis [8,12,19,21,22,33,34,37,39-46,48,51,52,54,56,57].
Included studies covered a total of 15,306 patients, with
an average of 567 patients per study (range 76 to 5,715).
The severe infection was BSI or bacteremia in 15
studies (55.5%) [8,12,19,21,22,33,36,37,39,46,47,50,52,55,56],
pneumonia in six studies (22.2%), [34,41,44,48,51,57], and
sepsis in three studies [38,42,45]; two studies described
severe sepsis or septic shock [40,54]. Severity of illness was
reported in 23 studies (85.2%) using a variety of severity
indexes, including the Acute Physiology and Chronic
Health Evaluation (APACHE) II [59], Charlson index [60],
the Sequential Organ Failure Assessment (SOFA) [61],
Simplified Acute Physiology Score (SAPS) II [62], Multiple
Organ Dysfunction Scale (MODS) [63], Pitt Bacteremia
score [64], and McCabe’s classification [65]. A signifi-
cant difference (P = 0.04) in illness severity between
the two groups was found in two studies [46,50].
However, nine studies [19,33,38,40,50-52,54,55] did
not compare the severity of illness between patients with
IAAT versus AAT.
Data on definition and measurement of (I)AAT
Data on the definition and the incidence of (I)AAT were
presented in Table 2. A spectrum of definitions exists in
the literature concerned. Fifteen (55.6%) studies included a
definition of AAT, four studies (14.8%) mentioned a
definition of IAAT, and eight studies (29.6%) defined
both. Thirty-two (94.1%) of the 34 definitions mentioned
the element ‘matching with the in vitro susceptibility’
or ‘intermediate or full in vitro resistance’. Other
frequently mentioned definitions items were the timing of
administration (n = 24, 70.6%), the correct dose (n = 8,
23.5%), and the correct indication for the antibiotics
(n = 6, 17.6%).
The percentage of empiric IAAT showed an enor-
mous range from 14.1% to 78.9% (median of 49, 26%,
interquartile range 28.1% to 57.8%). The magnitude of
this range can be explained in part by the differences
in the definitions, settings, diseases, and infectious agents.
Because of this considerable heterogeneity, it may be
misleading to quote an average value for the incidence.
However, 13 (48.1%) of these 27 studies described an
incidence of IAAT of 50% or more.Measurement of the dependent variable
Outcome was measured as mortality, LOS, and costs. A
meta-analysis was conducted to quantify the effect of
appropriateness in empiric antibiotics on mortality. The
number of studies that assess the total LOS [48,55], LOS
after infection onset [36,45], and the costs [37,48] were
very small. Therefore, these results are presented in a
descriptive manner only.
Mortality
In total, 26 studies [8,12,19,21,22,33,34,36-44,46-48,50,
51,54-57] reported mortality as an outcome variable in
patients with severe infection treated with (I)AAT.
However, the time span of mortality assessment varied
from 28 [34,55] to 30 [12,19,21,38,39,43,44,46,47,56] to 60
[51] days to 12 weeks [8]. Eleven studies [22,33,36,37,
40-42,48,50,54,57] assessed in-hospital mortality. Given
methodological considerations, meta-analysis on the effect
of AAT on 30-day mortality (n = 10) and in-hospital
mortality (n = 11) was conducted separately (Table 3).
Five [12,19,43,44,46] of the 10 studies reporting on
30-day mortality showed a significant lower mortality
for patients treated with AAT compared with those
treated with IAAT. Meta-analysis for 30-day mortality
revealed an RR of 0.71 (95% CI 0.62 to 0.82; P <0.0001)
in favor of AAT, without significant heterogeneity:
Cochran’s Q = 11.37, 9 degrees of freedom (d.f.), P = 0.252;
I2 = 20.8 (0% to 61%) (Figure 2). Of the 11 trials
[22,33,36,37,40-42,48,50,54,57] included in the meta-
analysis on in-hospital mortality, eight trials [33,40-42,
48,50,54,57] yielded significant lower mortality ratios in
patients receiving AAT. Meta-analysis for in-hospital
mortality revealed that an RR of 0.67 (95% CI 0.56
to 0.80; P <0.0001) in favor of AAT. However, there
was significant heterogeneity: Cochran’s Q = 74.45, 10 d.f.,
P <0.0001; I2 = 86.6 (77.8% to 91.9%) (Figure 3). Funnel
plots displayed an asymmetrical pattern for in-hospital
mortality but not for 30-day mortality studies. The re-
sults of the sensitivity analysis suggest that three
studies contribute to residual heterogeneity; removing
them from the meta-analysis would reduce variability
between studies. However, because this did not affect the
results, these studies were retained. Meta-regression
revealed that study quality (Down and Black score)
(P = 0.003), inclusion of a definition of appropriate
antibiotic usage (P = 0.0194), and studies reporting out-
come for sepsis (P = 0.0001) significantly influenced the
meta-analysis on in-hospital mortality.
The studies on 28-day [34,55] and 60-day [51] mortality
reported significantly higher mortality ratios in patients
receiving IAAT: respectively P = 0.007 [34], P = 0.001 [55],
and P = 0.023 [51]. The one study [8] that measures the
mortality rate at 12 weeks did not reveal a significant
difference (Table 4).
Table 2 Definition and incidence of (in)appropriate antibiotic therapy in the reviewed studies
Reference Appropriate empiric antibiotic therapy
Aspects of appropriate antibiotic therapy
Definition According to
the culture
Timing Dose According to
guidelines




Kim et al. [21]a Y Y Y N N Y N N N N 3
Kang et al. [12]a N
Micek et al. [33]a N
Luna et al. [34] Y Y N N Y N N N N N 2
Kim et al. [8] Y Y Y N N Y N N N N 3
Scarsi et al. [22]a Y Y Y Y Y N N N N N 4
Marschall et al. [36]a Y Y Y N N N N N N N 2
Shorr et al. [37]a Y Y Y N N N N N N N 2
Rodriguez-Bano et al. [38]a Y Y Y Y N Y N N N N 4
Ammerlaan et al. [39]a Y Y Y N N Y N N N N 3
Erbay et al. [19]a Y Y Y Y Y Y N N N N 5
Kumar et al. [40]a Y Y Y N N N N N N N 2
Tseng et al. [41]a Y Y N N N N Y N N N 2
Micek et al. [42]a Y Y Y N N N Y Y N N 4
Paul et al. [43]a Y Y Y N N N N N N N 2
Joung et al. [44]a Y Y Y Y N Y N N N N 4
Shorr et al. [45] N
Suppli et al. [46]a Y Y Y Y Y N Y Y Y N 7
Reisfeld et al. [47]a Y Y N Y N N N N N Y 3
Wilke et al. [48]a Y N N N Y N N N N N 1
Lye et al. [50]a Y Y N Y Y N N N N N 3
Tseng et al. [51] Y N N N N N Y N N N 1
Chen et al. [52] Y Y Y N N N N N N N 2
Labelle et al. [54]a Y Y Y N N N N N N N 2
Chen et al. [55] Y Y Y Y Y Y N N N N 5
Frakking et al. [56]a Y Y Y N N N N Y N N 3
Tumbarello et al. [57]a N










Table 2 Definition and incidence of (in)appropriate antibiotic therapy in the reviewed studies (Continued)
Reference Inappropriate empiric antibiotic therapy
Aspects of inappropriate antibiotic therapy
Definition Intermediate or full
in vitro resistance
Timing Omission Indication Route Number
of items
% IAAT
Kim et al. [21]a N 76.38
Kang et al. [12]a Y Y Y Y N N 3 52.80
Micek et al. [33]a Y Y N Y N N 2 24.59
Luna et al. [34] Y Y Y N N N 2 68.42
Kim et al. [8] N 49.16
Scarsi et al. [22]a Y Y Y N N N 2 14.14
Marschall et al. [36]a Y Y N Y N N 2 31.6
Shorr et al. [37]a N 76.98
Rodriguez-Bano et al. [38]a N 78.95
Ammerlaan et al. [39]a Y Y Y Y Y Y 5 28.14
Erbay et al. [19]a N 58.25
Kumar et al. [40]a Y Y Y N N N 2 19.88
Tseng et al. [41]a Y Y N N Y N 2 49.26
Micek et al. [42]a N 31.32
Paul et al. [43]a N 67.06
Joung et al. [44]a Y Y Y N N N 2 57.76
Shorr et al. [45] Y Y Y Y N N 3 31.30
Suppli et al. [46]a N 25.51
Reisfeld et al. [47]a N 39.95
Wilke et al. [48]a N 51.58
Lye et al. [50]a N 43.56
Tseng et al. [51] N 56.44
Chen et al. [52] N 38.98
Labelle et al. [54]a N 51.88
Chen et al. [55] N 27.21
Frakking et al. [56]a N 63.36
Tumbarello et al. [57]a Y Y N N N N 1 50.91
Total 11 11 7 5 2 1










Table 3 Summary of mortality data included in the meta-analysis
Reference Time of mortality assessment AAT mortality rate, % IAAT mortality rate, % P value
Kim et al. [21] 30 36.67 41.24 0.36
Kang et al. [12] 30 27.41 38.41 0.049
Micek et al. [33] IHM 17.83 30.67 0.018
Scarsi et al. [22] IHM 16.07 13.60 0.48
Marschall et al. [36] IHM 14.03 13.92 1.0
Shorr et al. [37] IHM 11.94 19.64 0.15
Rodríguez-Baño et al. [38] 30 18.18 24.24 0.3
Ammerlaan et al. [39] 30 25.00 21.27 NS
Erbay et al. [19] 30 39.53 65.00 0.011
Kumar et al. [40] IHM 48.00 89.70 <0.0001
Tseng et al. [41] IHM 35.44 50.00 OR 2.17 (1.4-3.38) 0.001
Micek et al. [42] IHM 36.40 51.68 <0.001
Paul et al. [43] 30 33.33 49.12 0.001
Joung et al. [44] 30 22.45 49.25 <0.0001
Suppli et al. [46] 30 20.55 40.00 0.009
Reisfeld et al. [47] 30 33.48 46.36 OR 1.4 (0.86-2.29) (NS)
Wilke et al. [48] IHM 14.02 26.32 0.021
Lye et al. [50] IHM 19.16 26.19 OR 0.67 (0.46-0.96) 0.03
Labelle et al. [54] IHM 51.38 68.30 <0.001
Frakking et al. [56] 30 18.82 20.41 NS
Tumbarello et al. [57] IHM 24.07 64.29 <0.001
AAT, appropriate antibiotic therapy; IAAT, inappropriate antibiotic therapy; IHM, in-hospital mortality; OR, odds ratio; NS, not significant.
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Four studies reported the effect on LOS: total LOS [48,55]
or LOS after the onset of infection [36,45]. In one of the
two studies [45], the mean LOS after infection onset was
significantly (P = 0.022) higher in the group sepsis patients
with IAAT. This indicates that IAAT independently in-
creased the median attributable LOS by 2 days. However,Study
Random effects model
Heterogeneity: I−squared=20.8%, tau−squared=0.0105, p=0.2515
Kim et al., 2004
Kang et al., 2005
Rodriguez−Bano et al., 2009
Ammerlaan et al., 2009
Erbay et al., 2009
Paul et al., 2010
Joung et al., 2010
Suppli et al., 2011
Reisfeld et al., 2011



















































Figure 2 Forest plot showing the effectiveness of appropriateness emthe study by Marschall et al. [36] found no significant
differences in LOS post-onset (P = 0.09) in patients with
Gram-negative bacteraemia. Appropriately treated pa-
tients with ventilator-associated pneumonia had a signifi-
cantly shorter total LOS (P = 0.022) [48]. Nevertheless,
Chen et al. [55] found no differences in the total LOS of






































pirical antibiotics in severe infections on 30-day mortality.
Study
Random effects model
Heterogeneity: I−squared=86.6%, tau−squared=0.0557, p<0.0001
Micek et al., 2005
Scarsi et al., 2006
Marschall et al., 2008
Shorr et al., 2008
Kumar et al., 2009
Tseng et al., 2009
Micek et al., 2010
Wilke et al., 2011
Lye et al., 2012
Labelle et al., 2012
































































































Figure 3 Forest plot showing the effectiveness of appropriateness empirical antibiotics in severe infections on in-hospital mortality.
Marquet et al. Critical Care  (2015) 19:63 Page 9 of 12The costs were assessed in only two studies [37,48]. The
total costs for patients with IAAT were significantly higher
in both studies (P ≤0.01).
Discussion
The incidence of patients with severe infections is sub-
stantial. Previous studies confirmed—as proven by the
low number needed to treat—that correct antibiotic
treatment is a crucial determinant of therapeutic success
[66]. Therefore, a systematic review with meta-analysis
was conducted to investigate the incidence and conse-
quences of IAAT on the outcome in hospitalized pa-
tients with infection.
Definitions and criteria items used to denote (I)AAT
varied substantially between studies. However, most defi-
nitions included the criterion ‘matching with the in vitro
susceptibility’ or ‘intermediate or full in vitro resistance’.
The timing of administration of the antibiotics was taken
into account in only 71% of the definitions. Timing of
admission is, however, an important aspect of adequate
antibiotic therapy. In patients with septic shock, each
hour of delay in antimicrobial therapy is associated with
an average decrease in survival of 7.6% [13]. Rivers et al.
[67] showed that early goal-directed therapy providesTable 4 Overview of studies evaluating the mortality rate at 2
Reference Time of mortality assessment AAT m
Luna et al., 2006 [34] 28 days 29.17
Chen et al., 2013 [55] 28 days 9.09
Tseng et al., 2012 [51] 60 days 28.17
Kim et al., 2006 [8] 12 weeks 28.10
AAT, appropriate antibiotic therapy; IAAT, inappropriate antibiotic therapy; NS, not ssignificant benefits with respect to outcome in patients
with severe sepsis and septic shock. For patients with
Staphylococcus aureus bacteraemia, the breakpoint be-
tween delayed and early treatment was 44.75 hours, and
delayed treatment was found to be an independent pre-
dictor of infection-related mortality [68]. Based on this
heterogeneity in the definitions, it was impossible to es-
timate the overall incidence of IAAT. However, IAAT
ranged from 14.1% to 78.9%, and 46.4% of studies de-
scribed an incidence of IAAT of 50% or more. Given this
high incidence, health-care professionals must become
aware of this problem. Moreover, in an era of rising anti-
microbial resistance rates, choosing empiric AAT is an
increasing challenge. The meta-analysis, involving 13,014
patients, suggests that the empiric AAT reduces 30-day
mortality (RR 0.71, 95% CI 0.62 to 0.82) and in-hospital
mortality (RR 0.67, 95% CI 0.56 to 0.80). In addition, em-
piric AAT positively affects LOS and costs.
Strengths of this study include the comprehensive
search strategy, the methodological quality assessment,
and the random-effects model analysis combined with
meta-regression. Besides the methodological strengths,
the study has limitations. First, the present findings
should be interpreted in the context of the included8 and 60 days and 12 weeks
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tients’ characteristics, definitions of IAAT, and the time
span of outcome assessment. Second, the lack of RCTs
is this review could be seen as a major limitation. The
lack of RCTs regarding this topic stems from obvious
ethical constraints. Given the methodological heterogen-
eity of the included (retro- and prospective) observa-
tional studies, an overall meta-analysis was impossible.
Meta-analysis was performed for 30-day and in-hospital
mortality only. Third, several potential biasing and con-
founding elements might have hampered this meta-
analysis. The reported diseases and the diagnosis
process, the study quality quantified by the Downs and
Black instrument, the quality of the health-care systems
in the different countries, and the definitions of adequate
antibiotic therapy had a marked influence on the meta-
analysis of in-hospital mortality. Nevertheless, we aggre-
gated all reported diseases to avoid a small numbers
problem. Probably the cleanest data for assessing the im-
pact of (I)AAT would be for bacteremia, as this is the in-
fection that can most accurately be defined. Fourth, this
analysis does not cover all areas, such as fungemiae.
However, this limitation creates opportunities for further
research. Fifthly, we used the (criteria of the) definitions
used in the included studies. Most of the studies
approached the definition one-sided and used only the
criteria ‘matching with the culture’ and ‘according to the
guidelines’. However, appropriateness of antibiotic treat-
ment is related not only to the substance itself but also
to dosing or administration route (or both) of the anti-
biotic. Finally, during this review, we focused on (in)ap-
propriate antibiotic therapy. Off course, inappropriate
therapy is not only determined by the antibiotic used.
Further research could focus on other aspects of (in)ap-
propriate therapy.
Conclusions
This systematic review demonstrates a very high inci-
dence of IAAT in patients with severe bacterial infection,
such as BSI, pneumonia, sepsis, or septic shock. Accur-
ate empirical treatment of these severe infections is not
a simple process seen in currently reported rates of
IAAT. Meta-analysis provides evidence that empiric in-
appropriate use of empiric antibiotics increases 30-day
and in-hospital mortality in these patients. Clinicians
should be aware of this problem, and further improve-
ment actions should be taken. Inappropriate antibiotic
treatment stems from several causes, mainly due to resist-
ance; therefore, it is not easy to find the most appropriate
treatment option. As long as general recommendations
about antibiotic stewardship are missing, problems will re-
main. Computerized decision support, including complex
and locally calibrated decision algorithms [69,70] or early
molecular identification or both, might be helpful.Key messages
 The definitions of IAAT varied. Nevertheless, almost
every definition included the element ‘matching with
the in vitro susceptibility’ or ‘intermediate or full
in vitro resistance’.
 This systematic review demonstrates a very high
incidence of empiric IAAT in patients with severe
infection, such as BSI, pneumonia, sepsis, or septic
shock.
 Meta-analysis provides evidence that empiric IAAT
increases 30-day and in-hospital mortality in
patients with a severe infection.
 Clinicians should be aware of this problem, and
further improvement actions should be taken.
Further computerized decision support needs to be
developed.Additional file
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